TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma

Abstract

BACKGROUND:

Immunogenomics approaches to the characterization of renal cell carcinoma (RCC) have helped to better our understanding of the features of RCC immune dysfunction. However, much is still unknown with regard to specific immune interactions and their impact in the tumor microenvironment.

OBJECTIVE:

This study applied chemical complementarity scoring for the TRB complementarity determining region-3 (CDR3) amino acid sequences and cancer testis antigens (CTAs) to determine whether such complementarity correlated with survival and the expression of immune marker genes.

METHODS:

TRB recombination reads from RCC tumor samples from RNAseq files obtained from two separate databases, Moffitt Cancer Center and The Cancer Genome Atlas (TCGA), were evaluated. Chemical complementarity scores (CSs) were calculated for TRB CDR3-CTA pairs and survival assessments based on those CSs were performed.

RESULTS:

Moffitt Cancer Center and TCGA cases representing the upper 50 ${}^{\text{th}}$ percentile of chemical CSs for TRB CDR3 amino acid sequences and the CTA POTEA were found to be associated with a better overall survival (OS) Also, greater tumor RNA expression of multiple immune signature genes, including granzyme A, granzyme B, and interferon-gamma were correlated with the higher chemical CSs.

CONCLUSIONS:

These results indicate that TRB CDR3-CTA chemical complementarity scoring may be useful in distinguishing RCC cases with a productive, anti-tumor immune response from cases where basic immune parameter assessments are inconsistent with a productive immune response.

Keywords

Renal cell carcinoma chemical complementarity immune signature genes TRB CDR3 Interactions with cancer testis antigens

1. Introduction

Numerous and varied genomics approaches have been applied for the analysis of renal cell carcinoma (RCC) In one approach, sequencing of primary tumors was used to track RCC evolution and to study the relationship between intratumor heterogeneity and patient outcomes, consistent with the conclusion that evolutionary subtypes determined by driver mutations or chromosomal abnormalities play a role in patterns of metastases and outcomes [1]. Many immunology approaches have focused on categorizing immune dysfunction in metastatic RCC, with worse prognosis indicated by terminally exhausted CD8+ T cells, decreased levels of pro-inflammatory macrophages, and increased levels of suppressive M2-like macrophages [2, 3]. Interestingly, worse prognosis has been found to be associated with high CD8+ T cell infiltration indicating that immune dysfunction may have a critical function in RCC tumor aggressiveness [4]. CD8+ T cell-related molecular classifications have been suggested as possible predictors of prognosis and immunotherapeutic efficiency but thus far in RCC have been suboptimal guides [2, 5]. Additionally, a predictive model for prognosis and immunotherapeutic responses based upon 14 immune-associated genes has recently been suggested as an effective alternative for predicting RCC outcomes [5]. However, overall, there remains a lack of effective markers for subdivisions of RCC that would benefit from distinct immunotherapies.

RCC is typically resistant to chemotherapy and radiotherapy, so immuno-therapeutics have become increasingly important and promising components of treatment [6].

Before the introduction of immunotherapeutics, many treatments involved targeted therapies such as tyrosine kinase inhibitors for the VEGF or mTOR signaling pathways; current therapies have improved effectiveness by incorporating immunotherapeutics such as different combinations of immune checkpoint inhibitors, e.g., PD-L1 monoclonal antibodies with or without the addition of tyrosine kinase inhibitors [7]. Clinical decision making for immunotherapy choices is complex but often based upon parameters such as overall risk classification, pathologic features such as sarcomatoid status and presence of contraindications to immune checkpoint inhibitor therapy [7]. Future therapies will likely include new immune classifications and new immunotherapy-related agents in combination with currently accepted targets, such as mTOR [8].

In this report, we explored a TRB CDR3-candidate antigen chemical complementarity scoring algorithm [9, 10], particularly suited to the big data setting, and applied the algorithm to both Moffitt Cancer Center (MCC) and TCGA case sets. We sought to identify a subset of RCC cases with active and pronounced cytotoxic immune responses, in contrast with less refined approaches that raise questions about whether successful, anti-tumor, T-cell-based cytotoxicity is in effect.

2. Methods

2.1 Acquisition of the immune receptor (IR) recombination reads from the renal cell carcinoma (RCC) sample RNAseq files

Figure 1.

Kaplan-Meier (KM) analyses comparing OS probabilities for case IDs representing RCC and the upper and lower 50 ${}^{\text{th}}$ percentiles for Combo CSs for the TRB CDR3 AA sequences and the CTA, POTEA. (A) KM analysis of Moffitt Cancer Center case IDs comparing OS probabilities of the upper 50 ${}^{\text{th}}$ percentile (black line, 47 case IDs) and the lower 50 ${}^{\text{th}}$ percentile (grey line, 46 case IDs) for the Combo CSs. Logrank $p$ -value: 0.0814. (B) KM analysis of TCGA-KIRC case IDs comparing OS probabilities of the upper 50 ${}^{\text{th}}$ percentile (black line, 259 case IDs) and lower 50 ${}^{\text{th}}$ percentile (grey line, 259 case IDs) for the Combo CSs. Logrank $p$ -value: 0.1505.

The methods for extracting the TRB recombination reads, from the RNAseq datasets, along with the benchmarking of the connection of such recombination reads to basic tumor immunology features, have been extensively described [11, 12, 13, 14]. The software for the extraction of the recombination reads, along with readme files, is available at the following links. Any one link represents the complete collection of software needed, but the three different links have various, specific conveniences as may be desired: (i) https://github.com/bchobrut-USF/blanck_group; (ii) https://hub.docker.com/r/bchobrut/vdj; (iii) https://github.com/kcios/2021. The complete set of TRB recombination read data resulting from the extraction of the TRB recombination reads from the Moffitt Cancer Center files is available in supporting online material (SOM) Table S1 The TCGA (phs000178) RNAseq-based TRB recombination reads were accessed, via reference [15] according to database of genotypes and phenotypes (dbGaP) approval number 6300; the Moffitt Cancer Center data were accessed via Moffitt Cancer Center Scientific Review Protocol approvals provided in reference [11]; the Clinical Proteomic Tumor Analysis Consortium (CPTAC) RCC dataset (phs001287) was accessed via National Institutes of Health dbGaP project approval number 31752.

2.2 Calculation of the chemical complementarity scores (CSs) for CDR3-CTA pairs

The TRB CDR3-candidate antigen CSs were calculated according to reference [9]. The calculations were facilitated by the web tool, adaptivematch.com [16], which is publicly available and which has instructions for preparation of input files. The web tool has been extensively benchmarked in ref. [17] and further employed in refs. [16, 18]. Briefly, the chemical complementarity scoring algorithm aligns all available TRB CDR3s for a given case to a candidate antigen and engineers a stepwise approach to calculating chemical attractiveness, based on electrostatic and hydrophobic attraction (with the latter specifically based on Uversky hydropathy scores [10]). The algorithm returns the highest CS for each CDR3-candidate antigen pair. The resulting chemical CS score is referred to as Combo CS, thereby referencing the inclusion of both electrostatic and hydrophobic calculations to obtain the CS. Three example input files are available in the SOM, Tables S2–S4, with Table S2 representing TCGA-KIRC CDR3s; Table S3 representing the CTA, POTEA [19]; and Table S4 representing the TCGA-KIRC OS data publicly available via cbioportal.org. Tables S5 and S6 represent example adaptivematch.com output files.

2.3 Survival analyses

Survival analyses were performed as described [16, 20].

2.4 Multivariate analysis

A multivariate Cox regression analysis for OS was performed using the Statistical Package for the Social Sciences (SPSS). The input variables were CDR3-Fragment FPNTEIEEYHRPEKKSNE Combo CS upper and lower 50 ${}^{\text{th}}$ percentiles (as further detailed in Results), age, and the American Joint Committee on Cancer (AJCC) pathologic tumor stage. Case IDs missing one or more of these variables were excluded.

3. Results

3.1 Survival distinctions represented by Combo CSs of TRB CDR3 AA sequences and the CTA, POTEA

To determine whether chemical complementarity between TRB CDR3 AA sequences and CTAs was associated with overall survival (OS) distinctions, we assessed Combo CSs (Methods) for the TRB CDR3 AA sequences and the AA sequences of multiple CTAs [9, 10, 16, 21, 22, 23, 24, 25]. We found that, while not meeting the conventional standard of statistical significance, Moffitt Cancer Center case IDs representing the upper 50 ${}^{\text{th}}$ percentile of Combo CSs, with the CSs defined by TRB CDR3-POTEA assessments, trended toward a better OS probability (Fig. 1A). Similarly, we found that TCGA-KIRC case IDs representing the upper 50th percentile of Combo CSs for the TRB CDR3-POTEA combination associated with a better OS probability (Fig. 1B). In both the Moffitt Cancer Center and TCGA-KIRC sets, the CSs were based on TRB CDR3 AA sequences representing TRB recombination reads recovered from tumor specimen RNAseq files [15, 26]. Raw KM data are available in Table S7.

Figure 2.

KM analyses comparing OS probabilities for case IDs representing the upper and lower 50 ${}^{\text{th}}$ percentiles for Combo CSs for the TRB CDR3s and Fragment FPNTEIEEYHRPEKKSNE from the CTA, POTEA. (A) KM analysis of Moffitt Cancer Center case IDs comparing OS probabilities of the upper 50 ${}^{\text{th}}$ percentile (black line, 47 case IDs) and lower 50 ${}^{\text{th}}$ percentile (grey line, 46 case IDs) for the Combo CSs. Logrank $p$ -value: 0.1351. (B) KM analysis of TCGA-KIRC case IDs comparing OS rates of the upper 50 ${}^{\text{th}}$ percentile (black line, 259 case IDs) and bottom 50 ${}^{\text{th}}$ percentile (grey line, 259 case IDs) of combo CSs. Logrank $p$ -value: 0.0932.

3.2 Survival distinctions represented by Combo CSs of TRB CDR3 AA sequences and the peptide fragment FPNTEIEEYHRPEKKSNE from the CTA, POTEA

To determine whether chemical complementarity between the TRB CDR3 AA sequences and a POTEA fragment was further associated with OS distinctions, we assessed the Combo CSs for the TRB CDR3 AA sequences and the AA sequence of fragment FPNTEIEEYHRPEKKSNE, among other POTEA fragments (Table S3). Results indicated that the Moffitt Cancer Center case IDs representing the upper 50 ${}^{\text{th}}$ percentile of Combo CSs, with the CSs defined by TRB CDR3-fragment FPNTEIEEYHRPEKKSNE assessments, represented a trend with a better OS probability (Fig. 2A). Similarly, we found that the upper 50 ${}^{\text{th}}$ percentile of Combo CSs in the TCGA-KIRC case ID set, representing TRB CDR3-fragment FPNTEIEEYHRPEKKSNE pairs, were associated with a better OS probability (Fig. 2B). Again, for both the Moffitt Cancer Center and TCGA-KIRC sets, the CSs were based on TRB CDR3 AA sequences representing TRB recombination reads recovered from tumor specimen RNAseq files [9, 10].

Figure 3.

Correlation between tumor RNA expression of immune signature genes and TRB CDR3-Fragment FPNTEIEEYHRPEKKSNE Combo CSs. Each point represents a case from the TCGA-KIRC database. (A) Scatterplot with linear regression line correlating RNA expression of granzyme A and Combo CSs (518 case IDs). (B) Scatterplot with linear regression line correlating RNA expression of granzyme B and Combo CSs (518 case IDs). (C) Scatterplot with linear regression line correlating RNA expression of interferon-gamma and Combo CSs (518 case IDs).

Table 1

Correlation between TCGA-KIRC RNA expression of immune signature genes and Combo CSs for the TRB CDR3 AA sequences and POTEA Fragment FPNTEIEEYHRPEKKSNE (See also Table S8)

Gene	Pearson’s coefficient	Pearson’s $p$ -value
CD4	0.415288	5.15E-23
CD3D	0.388963	3.72E-20
ICOS	0.385901	7.70E-20
CD86	0.364183	1.09E-17
GZMA	0.361984	1.76E-17
CD8A	0.35989	2.76E-17
CD33	0.348104	3.35E-16
CIITA	0.340664	1.53E-15
TNFRSF9	0.33171	9.05E-15
LAG3	0.319965	8.54E-14
IFNG	0.309279	6.05E-13

3.3 Correlation between Combo CSs and tumor microenvironment expression of immune genes

To determine whether expression of immune signature genes was associated with chemical complementarity, we assessed the correlation between TRB CDR3-fragment FPNTEIEEYHRPEKKSNE Combo CSs and the tumor RNA expression of multiple immune signature genes (Table 1). We found that TCGA-KIRC case IDs with greater tumor RNA expression of numerous immune signature genes including granzyme A, granzyme B, and interferon-gamma, among others, were associated with the higher Combo CSs (Table 1, Fig. 3). Additional data related to the correlation of the Combo CSs and immune signature gene expression is in Table S8.

3.4 Survival distinctions represented by expression of immune genes independently of TRB CDR3-POTEA chemical complementarity scoring

We determined whether RNA expression of immune signature genes in the total RCC dataset was associated with OS distinctions. Results indicated that TCGA case IDs representing the upper 50 ${}^{\text{th}}$ percentile of RNA expression for granzyme A (logrank $p$ -value $=$ 0.11), granzyme B (logrank $p$ -value $=$ 0.07), and interferon-gamma (logrank $p$ -value $=$ 0.006) were each associated with worse OS probabilities (Table S9).

Table 2
Correlation between CPTAC RCC RNA expression of immune signature genes and Combo CSs for the TRB CDR3 AA sequences and POTEA Fragment FPNTEIEEYHRPEKKSNE (See also Table S10)

Gene	Pearson’s coefficient	Pearson’s $p$ -value
ICOS	0.351502547	9.68E-10
CD3D	0.329153076	1.19E-08
CD4	0.328719512	1.24E-08
GZMA	0.309325562	9.31E-08
CD33	0.301787159	1.96E-07
CD86	0.26581085	5.17E-06
PDCD1LG2	0.261300781	7.55E-06
CD8A	0.259555912	8.72E-06
PDCD1	0.254483073	1.32E-05
MS4A1	0.250697365	1.79E-05

3.5 Replication of the correlation of the TRB-POTEA fragment (FPNTEIEEYHRPEKKSNE) CSs with the CPTAC RCC dataset

We mined the CPTAC RNAseq files for TRB recombination reads using the same approach described above for the Moffitt Cancer Center dataset (Methods; Table S10). We then obtained the Combo CSs for the TRB CDR3-POTEA fragment, FPNTEIEEYHRPEKKSNE, and determined any correlations for the Combo CS value for each CPTAC RCC case and the expression of the immune signature gene set, exactly as was done for Table 1, using a Pearson’s correlation assessment. Results indicated a substantial correspondence of the direct correlation of the Combo CS values and the level of expression of genes representing the immune signature set for both the TCGA and CPTAC datasets (Table 2).

Table 3
Multivariate Cox regression analysis. Age was analyzed on a continuous scale, while the upper and lower 50th percentiles for TRB CDR3-POTEA Fragment FPNTEIEEYHRPEKKSNE Combo CSs and tumor stages were treated as categorical variables. (Tumor stage I was used as a reference category)

Variable	B-factor	$p$ -value
TRB CDR3-POTEA Fragment FPNTEIEEYHRPEKKSNE upper and lower 50th percentiles of Combo CSs	$-$ 0.474	0.02
Age	0.033	$<$ 0.001
Tumor Stage I	NA	$<$ 0.001
Tumor Stage II	0.285	0.368
Tumor Stage III	0.972	$<$ 0.001
Tumor Stage IV	2.001	$<$ 0.001

3.6 Multivariate analysis

A multivariate Cox regression analysis was performed to detect potential variables that may be impacting OS including age and tumor stage, as well as the upper and lower 50 ${}^{\text{th}}$ percentiles of the TRB CDR3-Fragment FPNTEIEEYHRPEKKSNE Combo CSs. While each of these variables with the exception of Tumor Stage II were statistically significant, the only variable independently indicating an association with improved OS, rather than worse OS, was the upper 50 ${}^{\text{th}}$ percentile of TRB CDR3-Fragment FPNTEIEEYHRPEKKSNE Combo CSs (Table 3).

4. Discussion

This study was designed to determine whether chemical complementarity between CDR3s and CTAs could be used to subdivide RCC into groups with better or worse survival probabilities, and whether those groups could be correlated with additional features of an immune response. We focused on TRB CDR3 amino acid sequences in our approach because TRB represents the highest standard for direct contacts to an antigen in antigen binding to the T-cell receptor [27, 28, 29, 30, 31, 32, 33, 34]. We found an increased OS probability represented by cases with greater TRB CDR3-POTEA chemical complementarity, with similar results for cases with a greater TRB CDR3-POTEA Fragment FPNTEIEEYHRPEKKSNE chemical complementarity. We also identified greater RNA expression of multiple immune signature genes, notably including granzyme A, granzyme B, and interferon-gamma, in tumors with greater TRB CDR3-Fragment FPNTEIEEYHRPEKKSNE Combo CSs. One potential interpretation of these results is that improved tumor-resident, TRB CDR3 binding to the tumor antigen POTEA, or a fragment of this antigen, results in downstream immune effects that positively affect survival The association of high CS and better OS in the RCC setting is consistent with a similar study for MAGE CTAs and melanoma [17], but distinct from studies of lower grade glioma and ovarian cancer where the immune receptor-CTA CSs are inversely correlated with OS [16, 35], potentially reflecting vestigial and eventually ineffectual immune responses against the CTAs. In these latter two cases, the CTAs at issue were not expressed, further suggesting the possibility that the high CSs for the CTAs led to selection against early cancer cells expressing those CTAs.

The evidence that higher Combo CSs are related to better OS and higher expression of immune signature gene RNA becomes especially interesting in the context of RCC, a cancer that typically faces progressive levels of immune dysfunction [2]. When not taking the complementarity scoring into consideration, i.e., by assessing the entire TCGA RCC set, we found worse OS probability in cases with greater RNA expression of multiple immune signature genes. This result is consistent with a previous study that found that some immune genes, such as IFNG, correlate with greater occurrence of cytotoxic T cells, which in RCC correlates with higher stage and grade of tumors [36]. The contrast between the results from the global RCC set assessment and assessing the RCC cases by CSs indicates that complementarity scoring may be useful in distinguishing productive from non-productive or even harmful immune responses.

One recent study found that immune gene expression has shown promise in classifying solid tumors according to active favorable or unfavorable cytotoxic T cell responses, thereby identifying parameters that could potentially be used to refine current biomarkers for diagnosis and prognosis or to predict therapeutic responsiveness to treatments [37]. Another study identified a signature of five immune genes that predicted prognosis for RCC and that could potentially help in selecting patients for immune checkpoint inhibitor therapy [38]. We propose that chemical complementarity scoring could be included when searching for parameters to further improve the accuracy of molecular markers. Especially for cases of metastatic RCC, current prognostic factors have limited accuracy; it has been proposed that further refinement and validation of molecular markers should be a research priority [39].

It’s important to note that our analyses relied upon correlations, and that the mechanisms and downstream effects from TRB CDR3s binding to various RCC CTAs remains unverified by in vitro or in vivo approaches. Thus, it would be useful to extend the results indicated here to in vitro binding experiments whereby specific TRB CDR3s are tested for their affinity for the CTA, POTEA, as well as to consider animal models whereby POTEA is assessed as a potential antigen for RCC.

5. Conclusion

Chemical complementarity scoring, based on tumor resident, TRB CDR3s and cancer testis antigens can likely be used to distinguish productive versus harmful immune environments in renal cell carcinoma.

Disclosures

Informed Consent: Not applicable.

Registry and the Registration No. of the study/trial: Not applicable for clinical trial, but applicable for access to data, per Ethics approvals below.

Animal Studies: Not applicable

Ethics approvals

Access to TCGA-KIRC, RNAseq based TRB recombination reads was via dbGaP approval number 6300; access to the Moffitt Cancer Center RNAseq files was via protocol approvals available in reference [11]; access to the CPTAC RNAseq files was via dbGaP approval number 31752.

Author contributions

TRH: CONCEPTION; INTERPRETATION, OR AN-ALY SIS OF DATA: PREPARATION OF THE MANUSCRIPT.

VRB: INTERPRETATION OR ANALYSIS OF DATA; PREPARATION OF THE MANUSCRIPT

AC: INTERPRETATION OR ANALYSIS OF DATA: PREPARATION OF THE MANUSCRIPT.

BJM: CONCEPTION; INTERPRETATION, OR ANALYSIS OF DATA: PREPARATION OF THE MANUSCRIPT.

BIC: CONCEPTION; INTERPRETATION, OR ANALYSIS OF DATA.

MJD: INTERPRETATION OR ANALYSIS OF DATA.

JJS: INTERPRETATION OR ANALYSIS OF DATA.

GB: CONCEPTION; INTERPRETATION, OR ANALYSIS OF DATA: PREPARATION OF THE MANUSCRIPT; SUPERVISION.

Abbreviations

AA	Amino acid
AJCC	American Joint Committee on Cancer
CDR3	Complementarity determining region-3
CPTAC	Clinical Proteomic Tumor Analysis Consortium
CS	(chemical) complementarity score
CTA	Cancer testis antigen
GZMA	Granzyme A
GZMB	Granzyme B
IFNG	Interferon-gamma
IR	(adaptive) immune receptor
KIRC	Kidney, renal cell carcinoma
mTOR,	Mammalian target of rapamycin
OS	Overall survival
POTE	Prostate, ovary, testis, and placenta expressed
POTEA	POTE ankyrin domain family member A
RCC	Renal cell carcinoma
SPSS	Statistical Package for the Social Sciences
TCGA	The cancer genome atlas
TRA	T-cell receptor alpha
TRB	T-cell receptor beta
VEGF	Vascular endothelial growth factor

Supplementary data

The supplementary files are available to download from https://dx-doi-org.web.bisu.edu.cn/10.3233/CBM-230047.

sj-csv-1-cbm-10.3233_CBM-230047.csv - Supplemental material

Supplemental material, sj-csv-1-cbm-10.3233_CBM-230047.csv

sj-csv-2-cbm-10.3233_CBM-230047.csv - Supplemental material

Supplemental material, sj-csv-2-cbm-10.3233_CBM-230047.csv

sj-csv-3-cbm-10.3233_CBM-230047.csv - Supplemental material

Supplemental material, sj-csv-3-cbm-10.3233_CBM-230047.csv

sj-csv-4-cbm-10.3233_CBM-230047.csv - Supplemental material

Supplemental material, sj-csv-4-cbm-10.3233_CBM-230047.csv

sj-csv-5-cbm-10.3233_CBM-230047.csv - Supplemental material

Supplemental material, sj-csv-5-cbm-10.3233_CBM-230047.csv

sj-xlsx-1-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Supplemental material, sj-xlsx-1-cbm-10.3233_CBM-230047.xlsx

sj-xlsx-2-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Supplemental material, sj-xlsx-2-cbm-10.3233_CBM-230047.xlsx

sj-xlsx-3-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Supplemental material, sj-xlsx-3-cbm-10.3233_CBM-230047.xlsx

sj-xlsx-4-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Supplemental material, sj-xlsx-4-cbm-10.3233_CBM-230047.xlsx

sj-xlsx-5-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Supplemental material, sj-xlsx-5-cbm-10.3233_CBM-230047.xlsx

Footnotes

Acknowledgments

The authors thank USF research computing and Ms. Corinne Walter for extensive admin support of the database approval processes. The authors thank Moffitt Collaborative Data Services for database assistance. The authors thank the taxpayers of the State of Florida.

Conflict of interest

The authors have nothing to declare.

References

Bailey

Black

J.R.M.

Reading

J.L.

Litchfield

Turajlic

McGranahan

Jamal-Hanjani

and Swanton

, Tracking Cancer Evolution through the Disease Course, Cancer Discovery 11 (2021), 916–932.

Braun

D.A.

Street

Burke

K.P.

Cookmeyer

D.L.

Denize

Pedersen

C.B.

Gohil

S.H.

Schindler

Pomerance

Hirsch

Bakouny

Hou

Forman

Huang

Cui

Keskin

D.B.

Steinharter

Bouchard

Sun

Pimenta

E.M.

Mahoney

K.M.

McGregor

B.A.

Hirsch

M.S.

Chang

S.L.

Livak

K.J.

McDermott

D.F.

Shukla

S.A.

Olsen

L.R.

Signoretti

Sharpe

A.H.

Irizarry

R.A.

Choueiri

T.K.

and Wu

C.J.

, Progressive immune dysfunction with advancing disease stage in renal cell carcinoma, Cancer Cell 39 (2021), 632–648 e638.

Hajiran

Chakiryan

Aydin

A.M.

Zemp

Nguyen

Laborde

J.M.

Chahoud

Spiess

P.E.

Zaman

Falasiri

Fournier

Teer

J.K.

Dhillon

McCarthy

Moran-Segura

Katende

E.N.

Sexton

W.J.

Koomen

J.M.

Mule

Kim

and Manley

, Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response, Clinical and Experimental Immunology 204 (2021), 96–106.

Vuong

Kotecha

R.R.

Voss

M.H.

and Hakimi

A.A.

, Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma, Cancer Discovery 9 (2019), 1349–1357.

Feng

Zhao

Wei

Guo

Yang

Fang

Wei

Jiang

and Luo

, Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer, Frontiers in Immunology 12 (2021), 762120.

Jian

Yang

Sun

Zhao

Huang

Aldanakh

Zhang

Yang

and Wang

, Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma, Frontiers in Immunology 12 (2021), 639636.

Aeppli

Schmaus

Eisen

Escudier

Grunwald

Larkin

McDermott

Oldenburg

Porta

Rini

B.I.

Schmidinger

Sternberg

C.N.

Rothermundt

and Putora

P.M.

, First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts, ESMO Open 6 (2021), 100030.

Makhov

Joshi

Ghatalia

Kutikov

Uzzo

R.G.

and Kolenko

V.M.

, Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies, Mol Cancer Ther 17 (2018), 1355–1364.

Chobrutskiy

B.I.

Chobrutskiy

Zaman

Yeagley

Huda

T.I.

and Blanck

, High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer, Molecular Immunology 135 (2021), 247–253.

10.

Chobrutskiy

B.I.

Yeagley

Tipping

Zaman

Diviney

Patel

D.N.

Falasiri

Uversky

V.N.

and Blanck

, Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma, Oncogene 39 (2020), 1773–1783.

11.

Ferrall-Fairbanks

M.C.

Chakiryan

N.H.

Chobrutskiy

B.I.

Kim

Teer

J.K.

Berglund

Mule

J.J.

Fournier

Siegel

E.M.

Dhillon

Falasiri

S.S.A.

Arturo

J.F.

Katende

E.N.

Blanck

Manley

B.J.

and Altrock

P.M.

, Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma, Cancer Research 82 (2022), 929–942.

12.

Gill

T.R.

Samy

M.D.

Butler

S.N.

Mauro

J.A.

Sexton

W.J.

and Blanck

, Detection of Productively Rearranged TcR-alpha V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells, Cancer Inform 15 (2016), 23–28.

13.

Tong

W.L.

Y.N.

Samy

M.D.

Sexton

W.J.

and Blanck

, Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer, Human Vaccines & Immunotherapeutics 13 (2017), 501–506.

14.

Chobrutskiy

B.I.

Zaman

Tong

W.L.

Diviney

and Blanck

, Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade, J Neurooncol 140 (2018), 697–704.

15.

Thorsson

Gibbs

D.L.

Brown

S.D.

Wolf

Bortone

D.S.

Ou Yang

T.H.

Porta-Pardo

Gao

G.F.

Plaisier

C.L.

Eddy

J.A.

Ziv

Culhane

A.C.

Paull

E.O.

Sivakumar

I.K.A.

Gentles

A.J.

Malhotra

Farshidfar

Colaprico

Parker

J.S.

Mose

L.E.

N.S.

Liu

Rader

Dhankani

Reynolds

S.M.

Bowlby

Califano

Cherniack

A.D.

Anastassiou

Bedognetti

Rao

Chen

Krasnitz

Malta

T.M.

Noushmehr

Pedamallu

C.S.

Bullman

Ojesina

A.I.

Lamb

Zhou

Shen

Choueiri

T.K.

Weinstein

J.N.

Guinney

Saltz

Holt

R.A.

Rabkin

C.E.

Cancer Genome Atlas Research

Lazar

A.J.

Serody

J.S.

Demicco

E.G.

Disis

M.L.

Vincent

B.G.

and Shmulevich

, The Immune Landscape of Cancer, Immunity 48 (2018), 812–830 e814.

16.

Patel

A.R.

Patel

D.N.

Y.N.

Yeagley

Chobrutskiy

B.I.

and Blanck

, Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments, J Biomol Struct Dyn (2022), 1–9.

17.

Eakins

R.A.

Chobrutskiy

Teer

J.K.

Patel

D.N.

Hsiang

Huda

T.I.

Zaman

Sexton

W.J.

Coppola

Falasiri

Blanck

and Chobrutskiy

B.I.

, Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity, Molecular Immunology 150 (2022), 58–66.

18.

Huda

T.I.

Diaz

M.J.

Gozlan

E.C.

Chobrutskiy

B.I.

and Blanck

, Immunogenomics Parameters for Patient Stratification in Alzheimer’s Disease, J Alzheimers Dis (2022).

19.

Almeida

L.G.

Sakabe

N.J.

deOliveira

A.R.

Silva

M.C.

Mundstein

A.S.

Cohen

Chen

Y.T.

Chua

Gurung

Gnjatic

Jungbluth

A.A.

Caballero

O.L.

Bairoch

Kiesler

White

S.L.

Simpson

A.J.

Old

L.J.

Camargo

A.A.

and Vasconcelos

A.T.

, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Research 37 (2009), D816–819.

20.

Huda

T.I.

Mihyu

Gozlan

E.C.

Arndt

M.F.

Diaz

M.J.

Zaman

Chobrutskiy

B.I.

and Blanck

, Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates, Leukemia & Lymphoma (2021), 1–15.

21.

Yeagley

Chobrutskiy

B.I.

Gozlan

E.C.

Medikonda

Patel

D.N.

Falasiri

Callahan

B.M.

Huda

and Blanck

, Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas, Pediatr Hematol Oncol (2021), 1–14.

22.

Hsiang

Chobrutskiy

B.I.

Diaz

Huda

T.I.

Creadore

Zaman

Cios

K.J.

Gozlan

E.C.

and Blanck

, Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates, Transl Oncol 14 (2021), 101069.

23.

Arturo

J.F.

Chobrutskiy

B.I.

Yeagley

Patel

D.N.

Falasiri

Patel

J.S.

and Blanck

, Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates, Cell Mol Immunol 17 (2020), 776–778.

24.

Chobrutskiy

B.I.

Yeagley

Diviney

Zaman

Gozlan

E.C.

Tipping

Koohestani

D.M.

Roca

A.M.

and Blanck

, A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates, Immunology 159 (2020), 373–383.

25.

Chobrutskiy

B.I.

Zaman

Diviney

Mihyu

M.M.

and Blanck

, T-cell receptor-alpha CDR3 domain chemical features correlate with survival rates in bladder cancer, Journal of Cancer Research and Clinical Oncology 145 (2019), 615–623.

26.

Patel

D.N.

Yeagley

Arturo

J.F.

Falasiri

Chobrutskiy

B.I.

Gozlan

E.C.

and Blanck

, A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma, Int J Immunogenet 48 (2021), 409–418.

27.

Gowathaman

Pierce

B.G.

and Mariuzza

R.A.

, T cell receptors employ diverse strategies to target a p53 cancer neoantigen, The Journal of Biological Chemistry 298 (2022), 101684.

28.

Warshaviak

D.T.

Mkrtichyan

Munguia

M.L.

Lin

Chai

Pigott

Kang

Gallo

and Kamb

, Single variable domains from the T cell receptor beta chain function as mono- and bifunctional CARs and TCRs, Scientific Reports 9 (2019), 17291.

29.

Smith

N.L.

Nahrendorf

Sutherland

Mooney

J.P.

Thompson

Spence

P.J.

and Cowan

G.J.M.

, A Conserved TCRbeta Signature Dominates a Highly Polyclonal T-Cell Expansion During the Acute Phase of a Murine Malaria Infection, Frontiers in Immunology 11 (2020), 587756.

30.

Yohannes

D.A.

Kaukinen

Kurppa

Saavalainen

and Greco

, Clustering based approach for population level identification of condition-associated T-cell receptor beta-chain CDR3 sequences, BMC Bioinformatics 22 (2021), 159.

31.

Fischer

D.S.

Schubert

and Theis

F.J.

, Predicting antigen specificity of single T cells based on TCR CDR3 regions, Mol Syst Biol 16 (2020), e9416.

32.

Springer

Tickotsky

and Louzoun

, Contribution of T Cell Receptor Alpha and Beta CDR3, MHC Typing, V and J Genes to Peptide Binding Prediction, Frontiers in Immunology 12 (2021), 664514.

33.

Assmann

Kolijn

P.M.

Schrijver

van Gammeren

A.J.

Loth

D.W.

Ermens

Dik

W.A.

van der Velden

V.H.J.

and Langerak

A.W.

, TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients, Journal of Leukocyte Biology 111 (2022), 283–289.

34.

Kalergis

A.M.

and Nathenson

S.G.

, Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 beta of an MHC class I-restricted TCR, Journal of Immunology 165 (2000), 280–285.

35.

Barker

V.R.

Varkhedi

Patel

D.N.

Hsiang

Chobrutskiy

B.I.

and Blanck

, TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens? Am J Reprod Immunol, (2022).

36.

Akbarinejad

and Shahriyari

, Immune classification of clear cell renal cell carcinoma, Scientific Reports 11 (2021), 4338.

37.

Sherif

Roelands

Mifsud

Ahmed

E.I.

Raynaud

C.M.

Rinchai

Sathappan

Maaz

Saleh

Ozer

Fakhro

K.A.

Mifsud

Thorsson

Bedognetti

and Hendrickx

W.R.L.

, The immune landscape of solid pediatric tumors, J Exp Clin Cancer Res 41 (2022), 199.

38.

Hua

Chen

and Liang

, Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma, Aging (Albany NY) 12 (2020), 2302–2332.

39.

Klatte

Rossi

S.H.

and Stewart

G.D.

, Prognostic factors and prognostic models for renal cell carcinoma: a literature review, World J Urol 36 (2018), 1943–1952.

TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Methods

2.1 Acquisition of the immune receptor (IR) recombination reads from the renal cell carcinoma (RCC) sample RNAseq files

2.3 Survival analyses

2.4 Multivariate analysis

3. Results

3.1 Survival distinctions represented by Combo CSs of TRB CDR3 AA sequences and the CTA, POTEA

3.4 Survival distinctions represented by expression of immune genes independently of TRB CDR3-POTEA chemical complementarity scoring

Table 2 Correlation between CPTAC RCC RNA expression of immune signature genes and Combo CSs for the TRB CDR3 AA sequences and POTEA Fragment FPNTEIEEYHRPEKKSNE (See also Table S10)

Table 3 Multivariate Cox regression analysis. Age was analyzed on a continuous scale, while the upper and lower 50th percentiles for TRB CDR3-POTEA Fragment FPNTEIEEYHRPEKKSNE Combo CSs and tumor stages were treated as categorical variables. (Tumor stage I was used as a reference category)

4. Discussion

5. Conclusion

Disclosures

Ethics approvals

Author contributions

Abbreviations

Supplementary data

sj-csv-1-cbm-10.3233_CBM-230047.csv - Supplemental material

sj-csv-2-cbm-10.3233_CBM-230047.csv - Supplemental material

sj-csv-3-cbm-10.3233_CBM-230047.csv - Supplemental material

sj-csv-4-cbm-10.3233_CBM-230047.csv - Supplemental material

sj-csv-5-cbm-10.3233_CBM-230047.csv - Supplemental material

sj-xlsx-1-cbm-10.3233_CBM-230047.xlsx - Supplemental material

sj-xlsx-2-cbm-10.3233_CBM-230047.xlsx - Supplemental material

sj-xlsx-3-cbm-10.3233_CBM-230047.xlsx - Supplemental material

sj-xlsx-4-cbm-10.3233_CBM-230047.xlsx - Supplemental material

sj-xlsx-5-cbm-10.3233_CBM-230047.xlsx - Supplemental material

Footnotes

Acknowledgments

Conflict of interest

References

Table 2
Correlation between CPTAC RCC RNA expression of immune signature genes and Combo CSs for the TRB CDR3 AA sequences and POTEA Fragment FPNTEIEEYHRPEKKSNE (See also Table S10)

Table 3
Multivariate Cox regression analysis. Age was analyzed on a continuous scale, while the upper and lower 50th percentiles for TRB CDR3-POTEA Fragment FPNTEIEEYHRPEKKSNE Combo CSs and tumor stages were treated as categorical variables. (Tumor stage I was used as a reference category)